• "HTG technology allowed us to take our research further faster."

     

    Dr. Peter Ansell

    Scientific Director and Research Fellow

    Precision Medicine-Oncology

    AbbVie

     

    Read more

  • HTG is Accelerating Precision Medicine

    From diagnosis to treatment, HTG is harnessing the power of transcriptome-wide profiling to drive translational research, clinical diagnostics and targeted therapeutics across a variety of disease areas.

    Learn More

  • HTG Transcriptome Panel Available Now

    Simplify gene expression analysis with our new comprehensive human transcriptome panel.

    Learn More

 

Peter Ansell, Ph.D., Scientific Director and Research Fellow, Precision Medicine Oncology at AbbVie discussed how his team overcame many challenges they have previously faced using FFPE clinical samples by integrating HTG’s innovative HTG Transcriptome Panel (HTP) into their biomarker strategies.

Stream on-demand webinar

News & Events

The Festival of Genomics & Biodata 2023

January 25-26 | Come and see us in London at the 2023 Festival of Genomics

Posted on:

Keep Reading

HTG Molecular Diagnostics to Participate in the Cantor Fitzgerald Oncology, Hematology & HemeOnc Conference

TUCSON, Ariz. , Sept. 26, 2022 (GLOBE NEWSWIRE) –  HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today announced that management will participate in the Cantor Fitzgerald…

Keep Reading

The Fundación Instituto Valenciano de Oncología Leverages HTG Technology for Breast Cancer Laboratory-Developed Test

TUCSON, Ariz. , Sept. 20, 2022 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, announced that the Fundación Instituto Valenciano de Oncología, located in…

Keep Reading

HTG Molecular Diagnostics Reports Second Quarter 2022 Results

Call scheduled for today, August 11, 2022, at 4:30 pm ET TUCSON, Ariz. , Aug. 11, 2022 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today reported recent…

Keep Reading

Publications

Read white papers or journal publications and view other scientific content. 

Documents

Tech Notes

White Papers

Therapeutics

Posters

Abstracts

Peer Reviewed Publications

Editorials

Reviews


Careers at HTG

At HTG, we are always looking for talented individuals to help us deliver our next-generation sequencing-based products throughout the world.

New Careers

See All Careers


Page last updated July 29, 2022